Cargando…
The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391090/ https://www.ncbi.nlm.nih.gov/pubmed/34595943 http://dx.doi.org/10.18553/jmcp.2021.27.10.1495 |
| _version_ | 1785082623675072512 |
|---|---|
| author | Tice, Jeffrey A Mandrik, Olena Thokala, Praveen Fotheringham, James Pearson, Steven D |
| author_facet | Tice, Jeffrey A Mandrik, Olena Thokala, Praveen Fotheringham, James Pearson, Steven D |
| author_sort | Tice, Jeffrey A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10391090 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103910902023-08-02 The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council Tice, Jeffrey A Mandrik, Olena Thokala, Praveen Fotheringham, James Pearson, Steven D J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2021-10 /pmc/articles/PMC10391090/ /pubmed/34595943 http://dx.doi.org/10.18553/jmcp.2021.27.10.1495 Text en Copyright © 2021, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Tice, Jeffrey A Mandrik, Olena Thokala, Praveen Fotheringham, James Pearson, Steven D The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title | The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_full | The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_fullStr | The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_full_unstemmed | The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_short | The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_sort | effectiveness and value of belimumab and voclosporin for lupus nephritis: a summary from the institute for clinical and economic review’s new england comparative effectiveness public advisory council |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391090/ https://www.ncbi.nlm.nih.gov/pubmed/34595943 http://dx.doi.org/10.18553/jmcp.2021.27.10.1495 |
| work_keys_str_mv | AT ticejeffreya theeffectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT mandrikolena theeffectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT thokalapraveen theeffectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT fotheringhamjames theeffectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT ticejeffreya effectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT mandrikolena effectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT thokalapraveen effectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT fotheringhamjames effectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueofbelimumabandvoclosporinforlupusnephritisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil |